

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket 044508-5001

Application No. 09/762,261

Applicants: Gerald Quinnan et al.

Page 1 of 1

Filing Date: February 5, 2001

Group Art Unit: 1653

U.S. PATENT DOCUMENTS

Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Sub-Class	Translation

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

aa	<input checked="" type="checkbox"/>	Cotropia <i>et al.</i> (1996) A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates, <i>J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.</i> 12:221-232
ab	<input checked="" type="checkbox"/>	Hioe <i>et al.</i> (1997) Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies, <i>Int. Immunol.</i> 9:1281-1290
ac	<input checked="" type="checkbox"/>	Moore <i>et al.</i> (1993) Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V2 domains, <i>J. Virol.</i> 67:6136-6151
ad	<input checked="" type="checkbox"/>	Muster <i>et al.</i> (1993) A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1, <i>J. Virol.</i> 67:6642-6647
ae	<input checked="" type="checkbox"/>	Sabri <i>et al.</i> (1996) Lack of correlation between V3 amino acid sequence and syncytium-inducing capacity of some HIV type 1 isolates, <i>AIDS Res. Hum. Retroviruses</i> , 12:855-858
af	<input checked="" type="checkbox"/>	Thali <i>et al.</i> (1993) Characterization of conserved human immunodeficiency virus type-1 gp120 neutralization epitopes exposed upon gp120-CD4, <i>J. Virol.</i> 67:3978-3988
ag	<input checked="" type="checkbox"/>	Thali <i>et al.</i> (1994) Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type-1 gp120 glycoprotein conferred by a gp41 amino acid change, <i>J. Virol.</i> 68:674-680
ah	<input checked="" type="checkbox"/>	Trkola <i>et al.</i> (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope of human immunodeficiency virus type-1, <i>J. Virol.</i> 70:1100-1108
ai	<input checked="" type="checkbox"/>	VanCott <i>et al.</i> (1997) Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type-1 isolates elicited by immunization with oligomeric gp160, <i>J. Virol.</i> 71:4319-4330
aj	<input checked="" type="checkbox"/>	Zwart <i>et al.</i> (1991) Immunodominance and antigenic variation of the principal neutralization domain of HIV-1, <i>J. Virol.</i> 181:481-489.

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Attorney Docket
044508-5001Application No.
Not assigned

09/762261

Applicants:
Gerald V. Quinnan, Jr. *et al.*

Page 1 of 1

PTO Form 1449

Filing Date: February 5, 2001

Group Art Unit: Not assigned

U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
SH	5,622,933	4/22/97	Sabatier <i>et al.</i>	514	16	6/15/94
SH	5,756,674	5/26/98	Katinger <i>et al.</i>	530	350	6/7/95
SH	5,439,809	8/8/95	Haynes <i>et al.</i>	435	69.3	6/15/92

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Sub-Class	Translation

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner	<i>Sharon H. Feltz</i>	Date Considered	6/16/2
----------	------------------------	-----------------	--------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.